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encephalopathy in patients with compensated cirrhosis? 
Authors' reply
EDITORS,
We appreciate the letter from Li et al about our recently pub-
lished article on the association between opioids and hepatic en-
cephalopathy (HE).1,2 The letter raises interesting points deserving 
additional clarification.
While physicians worldwide may be cautious prescribing opioids, 
recent studies from the US demonstrate that opioids are prescribed 
at alarming rates for patients with cirrhosis.3,4 We found that opi-
oid prescriptions are independently associated with incident HE in 
younger patients with well compensated cirrhosis,2 validating sim-
ilar findings from the US Medicare population.5 This adds to many 
other potential harms of opioids in cirrhosis, including hospital re-
admissions,6 overdose7 and decreased health-related quality of life.8 
Furthermore, in a recent randomized trial of treatments for osteoar-
thritis and back pain, patients receiving opioids reported increased 
pain compared to the non-opioid group9 and, in cirrhosis, opioid use 
is associated with greater pain-related disability, even when adjust-
ing for the severity of pain.10 Based on opioids’ demonstrated risks, 
uncertain benefits and widespread use in the US, we feel justified 
in our conclusion that, when possible, opioids should be avoided in 
cirrhosis.
Without question, pain control is challenging in patients with cir-
rhosis given contraindications to commonly used analgesics like non-
steroidal anti-inflammatory drugs. There are some situations when 
short-term opioids are indicated (e.g. post-operative pain). However, 
with a well-reasoned approach, we believe that opioid-sparing strat-
egies are possible for most patients with cirrhosis. Clinicians should 
first identify and treat contributors to pain including comorbid sleep 
disturbances, anxiety/depression and substance use disorders.10 
First-line pharmacologic options, including low-dose acetaminophen 
(<2 g/day) and topical analgesics, should be routinely offered. For 
pain not responsive to first-line treatments, clinicians should pursue a 
multidisciplinary treatment approach including physical, behavioural, 
procedural and pharmacological aspects (Figure 1).11 When patients 
do require opioids, clinicians should be vigilant to detect and prevent 
HE, including use of empiric lactulose and/or rifaximin.
Lastly, Li et al state that we did not account for the severity 
of liver disease or indications for opioid prescriptions. We used a 
national insurance claims database that does not contain labora-
tory data, thus precluding assessment of model for end-stage liver 
disease. However, we did account for liver disease severity by 
carefully controlling for decompensation events. We failed to find 
evidence that opioid prescriptions were associated with incident 
non-HE decompensation events, suggesting that our results were 
not confounded by the severity of the liver disease. In fact, the 
annual incidence of non-HE decompensation events was nearly 
identical in patients with no opioid prescriptions (12.0%), short-
term opioids (12.0%) and chronic opioids (11.6%). Similarly, this 
database includes the type and duration of opioid prescriptions, 
but does not include information on the indication of opioids, 
precluding assessment of the ‘appropriateness’ of prescriptions. 
Nevertheless, this does not affect our conclusion that opioids, 
regardless of indication, were associated with an increased risk 
of HE.
In summary, given risks of opioids in patients with cirrhosis, we 
think their use should be limited. Broad employment of a multidis-
ciplinary approach to pain in cirrhosis could reduce the high preva-
lence of opioid use and decrease the incidence of HE.
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F I G U R E  1   Multidisciplinary approach to pain management in patients with cirrhosis. TENS, transcutaneous electrical nerve stimulation. 
*Caution in patients with coagulopathy [Colour figure can be viewed at wileyonlinelibrary.com]
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